Note 15 - Segment Information (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Sale of product	2023		2022
Theranostics products	$	6,842,898	$	6,045,767
Cobalt products		1,037,073		1,157,536
Nuclear medicine standards		4,387,414		3,978,685
Fluorine products		—		—
Total segments		12,267,385		11,181,988
Corporate revenue		—		—
Total consolidated	$	12,267,385	$	11,181,988

Depreciation and amortization	2023		2022
Theranostics products	$	25,287	$	63,493
Cobalt products		53,331		49,202
Nuclear medicine standards		114,833		114,990
Fluorine products		115,879		115,598
Total segments		309,330		343,283
Corporate depreciation and amortization		40,764		30,913
Total consolidated	$	350,094	$	374,196

Segment income (loss)	2023			2022
Theranostics products	$	3,037,375		$	4,182,151
Cobalt products		(126,504	)		(95,779	)
Nuclear medicine standards		386,592			39,223
Fluorine products		(105,099	)		(139,860	)
Total segments		3,192,364			3,985,735
Corporate loss		(4,061,380	)		(3,682,497	)
Total consolidated	$	(869,016	)	$	303,238

Expenditures for segment assets	2023		2022
Theranostics products	$	3,420	$	3,379
Cobalt products		49,774		17,105
Nuclear medicine standards		35,137		75,478
Fluorine products		—		4,100
Total segments		88,331		100,062
Corporate purchases		60,727		19,952
Total consolidated	$	149,058	$	120,014

Segment assets	2023		2022
Theranostics products	$	849,351	$	1,075,252
Cobalt products		274,513		406,629
Nuclear medicine standards		3,538,558		2,744,394
Fluorine products		4,980,118		5,147,325
Total segments		9,642,540		9,373,600
Corporate assets		7,262,547		6,870,996
Total consolidated	$	16,905,087	$	16,244,596